IQVIA Introduces Life Science Models to Predict Clinical Trial Outcomes
Research Triangle Park, N.C. — (Business Wire) – IQVIA (NYSE:IQV), a leading provider of clinical research services and healthcare intelligence, has unveiled its new IQVIA Life Science Models™ at TechIQ 2026. These innovative models are designed to enhance the prediction of clinical trial outcomes.
Key Features of IQVIA Life Science Models:
-
Clinical Study Simulation: The models offer tools for optimizing study protocols, including endpoint selection, dose selection, and sample size planning. In preliminary evaluations across 50 trials, 85% of predictions were accurate or clinically close.
-
Digital Twins and Synthetic Controls: This feature enables the design of more efficient studies.
-
Enhanced Real-World Planning: The models aid in leveraging clinical study predictions for improved real-world access and planning.
With these models, IQVIA builds on its Predictive Clinical Development approach, allowing sponsors to simulate studies and assess assumptions, thereby identifying potential risks and optimizing study design early in the process.
For further details on IQVIA Life Science Models, visit IQVIA’s official webpage.
About IQVIA
IQVIA provides actionable insights and services powered by high-quality health data, advanced analytics, and extensive domain expertise. The company focuses on responsible AI usage, privacy, and regulatory compliance, committed to advancing medical treatments and improving patient outcomes globally.
For more information, visit www.iqvia.com.
Media Contacts
-
Kerri Joseph, Investor Relations
Email: kerri.joseph@iqvia.com
Phone: +1.973.541.3558 -
Alissa Maupin, Media Relations
Email: alissa.maupin1@iqvia.com
Phone: +1.919.923.6785
